A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Gynecologic Oncology Group
Start Date
December 17, 2019
End Date
November 14, 2024
Administered By
Duke Cancer Institute
Awarded By
Gynecologic Oncology Group
Start Date
December 17, 2019
End Date
November 14, 2024